2025
The evolving role of liver biopsy: Current applications and future prospects
Gopal P, Hu X, Robert M, Zhang X. The evolving role of liver biopsy: Current applications and future prospects. Hepatology Communications 2025, 9: e0628. PMID: 39774070, PMCID: PMC11717517, DOI: 10.1097/hc9.0000000000000628.Peer-Reviewed Original Research
2023
Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine.
Gopal P, Robert M, Zhang X. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine. Archives Of Pathology & Laboratory Medicine 2023, 148: 359-370. PMID: 37327187, DOI: 10.5858/arpa.2022-0537-ra.Peer-Reviewed Original ResearchConceptsDiagnosis of cholangiocarcinomaImmune checkpoint inhibitorsAdvanced tumor stageHeterogeneous tumor groupTumor growth patternEra of precision medicineTherapeutic decision-makingEvaluation of cholangiocarcinomaExtrahepatic biliary treeGenetic testing methodologiesSite of originCheckpoint inhibitorsTumor inaccessibilityMetastatic adenocarcinomaPeriductal infiltrationTumor stageIntraductal tumorClinical presentationDifferentiate cholangiocarcinomaImmunohistochemical profileTumor groupExtrahepatic cholangiocarcinomaTargeted therapyPathological diagnosisIntrahepatic cholangiocarcinoma
2022
Cytoskeletal dynamics regulates stromal invasion behavior of distinct liver cancer subtypes
Nguyen RY, Xiao H, Gong X, Arroyo A, Cabral AT, Fischer TT, Flores KM, Zhang X, Robert ME, Ehrlich BE, Mak M. Cytoskeletal dynamics regulates stromal invasion behavior of distinct liver cancer subtypes. Communications Biology 2022, 5: 202. PMID: 35241781, PMCID: PMC8894393, DOI: 10.1038/s42003-022-03121-5.Peer-Reviewed Original Research
2021
Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy
Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. American Journal Of Clinical Pathology 2021, 156: 214-228. PMID: 33555016, DOI: 10.1093/ajcp/aqaa217.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseCD8/FOXP3 ratioBiopsy specimensCPI patientsPD-1CD68 scoreFOXP3 ratioBowel diseasePD-L1Antibody-treated patientsCheckpoint inhibitor colitisPD-L1 groupInitial biopsy specimensPD-L1 expressionImmune cell reactionsColonic biopsy specimensDrug-specific differencesIBD groupCheckpoint inhibitorsChronicity scoreActivity scoreImmune phenotypeTherapeutic responseColitisShared pathophysiology
2020
Immune Checkpoint Inhibitor–Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease
Irshaid L, Robert ME, Zhang X. Immune Checkpoint Inhibitor–Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. Archives Of Pathology & Laboratory Medicine 2020, 145: 191-200. PMID: 33501492, DOI: 10.5858/arpa.2019-0700-oa.Peer-Reviewed Original ResearchConceptsHelicobacter pylori gastritisUpper gastrointestinal tractCeliac diseasePylori gastritisCPI therapyCD8 ratioDuodenal biopsiesInflammatory changesLymphoid aggregatesGastrointestinal tractAnti-programmed death receptor-1/Anti-cytotoxic T-lymphocyteDeath receptor-1/Immune checkpoint inhibitor therapyImmune-related adverse eventsDeath ligand 1 antibodyColonic mucosal changesGastrointestinal tract inflammationLamina propria CD3Lamina propria inflammationUpper gastrointestinal biopsiesUpper gastrointestinal injuryCheckpoint inhibitor therapyH pylori gastritisCD8 T cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply